gongsijingguoliushiduonianlaizaiyiyaodajiankanglingyudeshengengxizuo,qixiayiyongyou40yujiagongsi,xingchengyi“yiyaopifa、yiyaolingshou、yiyaogongyeweizhuye,gongyinglianzengzhifuwu、yiyaohulianwangfuwu、zhongduanjiankangfuwudengchuangxinyewuxietongfazhan”dezonghexingyiyaodajiankangchanyejituan.
gongsijingguoliushiduonianlaizaiyiyaodajiankanglingyudeshengengxizuo,qixiayiyongyou40yujiagongsi,xingchengyi“yiyaopifa、yiyaolingshou、yiyaogongyeweizhuye,gongyinglianzengzhifuwu、yiyaohulianwangfuwu、zhongduanjiankangfuwudengchuangxinyewuxietongfazhan”dezonghexingyiyaodajiankangchanyejituan.
gongsijingguoliushiduonianlaizaiyiyaodajiankanglingyudeshengengxizuo,qixiayiyongyou40yujiagongsi,xingchengyi“yiyaopifa、yiyaolingshou、yiyaogongyeweizhuye,gongyinglianzengzhifuwu、yiyaohulianwangfuwu、zhongduanjiankangfuwudengchuangxinyewuxietongfazhan”dezonghexingyiyaodajiankangchanyejituan.
gongsijingguoliushiduonianlaizaiyiyaodajiankanglingyudeshengengxizuo,qixiayiyongyou40yujiagongsi,xingchengyi“yiyaopifa、yiyaolingshou、yiyaogongyeweizhuye,gongyinglianzengzhifuwu、yiyaohulianwangfuwu、zhongduanjiankangfuwudengchuangxinyewuxietongfazhan”dezonghexingyiyaodajiankangchanyejituan.
gongsijingguoliushiduonianlaizaiyiyaodajiankanglingyudeshengengxizuo,qixiayiyongyou40yujiagongsi,xingchengyi“yiyaopifa、yiyaolingshou、yiyaogongyeweizhuye,gongyinglianzengzhifuwu、yiyaohulianwangfuwu、zhongduanjiankangfuwudengchuangxinyewuxietongfazhan”dezonghexingyiyaodajiankangchanyejituan.
gongsijingguoliushiduonianlaizaiyiyaodajiankanglingyudeshengengxizuo,qixiayiyongyou40yujiagongsi,xingchengyi“yiyaopifa、yiyaolingshou、yiyaogongyeweizhuye,gongyinglianzengzhifuwu、yiyaohulianwangfuwu、zhongduanjiankangfuwudengchuangxinyewuxietongfazhan”dezonghexingyiyaodajiankangchanyejituan.
gongsijingguoliushiduonianlaizaiyiyaodajiankanglingyudeshengengxizuo,qixiayiyongyou40yujiagongsi,xingchengyi“yiyaopifa、yiyaolingshou、yiyaogongyeweizhuye,gongyinglianzengzhifuwu、yiyaohulianwangfuwu、zhongduanjiankangfuwudengchuangxinyewuxietongfazhan”dezonghexingyiyaodajiankangchanyejituan.
编者按:
药品不良反应信息通报制度是我国药品监督管理部门为保障公众用药安全而建立的一项制度。《药品不良反应信息通报》(以下简称《通报》)公开发布以来,对推动我国药品不良反应监测工作,保障广大人民群众用药安全起到了积极作用。
药品存在两重性,它具有治疗疾病的作用,但也存在一定的不良反应。对于特定疾病/症状和特定人群而言,考虑到患者群体的治疗需求,药品所带来的治疗利益大于可预见的风险,一般认为这个药品是安全的。药品上市前的审评和上市后的再评价,均是对药品治疗利益和固有风险的综合评价。
benqitongbaodeshi《jingtixianlinggubaokoufuzhijiyinqidegansunshangfengxian》。xianlinggubaokoufuzhijishiyileibushenzhuangguyao,linchuangshangyongyuguzhishusongheguzhishusongzheng、guzhe、guguanjieyan、guwujunxinghuaisideng。2013nianguojiayaopinbuliangfanyingjiancezhongxincengkaizhanduixianlinggubaokoufuzhijideanquanxingpingjia,bingyaoqiuqiyexiudingyaopinshuomingshu,tishigansunshangfengxian。cihou,guojiayaopinbuliangfanyingjiancezhongxinchixumiqiejiancegaipinzhong,jinqidefenxijieguoxianshi,zhangqilianxuyongyao、laonianhuanzheyongyaodengkenenghuizengjiazheizhongfengxian。weishiguangdayiwurenyuan、yaopinshengchanqiyehegongzhonglejiegaipinzhongdeanquanxingwenti,zhidaolinchuangheliyongyao,jiangdiyongyaofengxian,benqiduixianlinggubaokoufuzhijiyinqidegansunshangbuliangfanyingjinxingtongbao。
警惕仙灵骨葆口服制剂引起的肝损伤风险
xianlinggubaokoufuzhijishiyileibushenzhuangguyao,juyouzibuganshen、jieguxujin、qiangshenjiangudegongxiao,linchuangshangyongyuguzhishusongheguzhishusongzheng、guzhe、guguanjieyan、guwujunxinghuaisideng。
一、不良反应报告整体情况
2004nian01yue01ri-2016nian07yue21ri,guojiayaopinbuliangfanyingjianceshujukuzhonggongshoudaoxianlinggubaokoufuzhijibuliangfanyingbaogao2665li,qizhongyanzhongbaogao81li(3.1%)。xianlinggubaokoufuzhijidebuliangfanyingzhuyaobaokuoweichangxitongsunhai(55.6%)、pifujiqifujiansunhai(23.2%)、zhongshujiwaizhoushenjingxitongsunhai(5.5%)deng,buliangfanyingbiaoxianbaokuoexin、outu、pizhen、saoyang、futong、fuxie、fuzhang、xinji、xiongmen、gangongnengyichang、ganxibaosunhaideng。
二、肝损伤不良反应报告情况
在严重不良反应报告中,肝胆系统损害所占比例明显高于总体报告中的相应比例,不良反应表现包括肝酶水平升高、胆红素水平升高、肝细胞损害等。肝胆系统损害多见于中老年患者,其中45-64岁患者占40.5%,65岁以上患者占51.9%。 大多数(60.7%)肝损伤不良反应报告中的用药时间在30天以上。
典型病例1:患者女,56岁,因颈椎、腰椎疼痛服用仙灵骨葆胶囊,每日2次,每次3粒,约2个月后出现眼黄、尿黄、乏力、纳差,查肝生化指标:总胆红素:63.1μmol/L、谷丙转氨酶:832 U/L、谷草转氨酶:744 U/L,查肝炎病毒学,自身免疫性肝炎指标均呈阴性。停用仙灵骨葆胶囊,给予保肝对症治疗,2周后肝生化指标:总胆红素:19.77 μmol/L、谷丙转氨酶:156 U/L、谷草转氨酶:73 U/L。
典型病例2:患者女,60岁,12月12日因“骨盆骨折”服用“仙灵骨葆胶囊”,次年1月2日前出现乏力,食纳差,进食量减少至正常时的三分之一,厌油腻食物,恶心、呕吐四次胃内容物,尿色发黄,渐加深如浓茶水样。1月12日查肝生化指标:谷丙转氨酶:753.8 U/L、谷草转氨酶:1001.8 U/L、碱性磷酸酶:267.6 U/L、γ-谷氨酰转移酶:105.7 U/L、血白蛋白:37.3 g/L、总胆红素:116.1 μmol/L。随以“肝功能异常”收入院,入院后嘱休息,停服仙灵骨葆胶囊,给予保肝对症治疗。1月27日复查肝生化指标:谷丙转氨酶: 44 U/L、谷草转氨酶: 36 U/L、碱性磷酸酶:131 U/L、γ-谷氨酰基转移酶:66 U/L、总胆红素:36.3 μmol/L,好转出院。
dianxingbingli3:huanzhenv,79sui,yinyaozhuijianpantuchuzifuxianlinggubaojiaonang。4geyuehouzijuefali、nacha,niaoweinongchase,qiepifuhuangran,12yue7richashenghuazhibiao:zongdanhongsu:405μmol/l、zhijiedanhongsu:237μmol/l、gubingzhuananmei:1250 u/l、gucaozhuananmei:1351 u/l、γ-guanxianzhuanyimei:129 u/l、jianxinglinsuanmei:128 u/l、xuebaidanbai:28 g/l、qiudanbai:25 g/l、ningxuemeiyuanshijian:37.3 s,huodongdu<40%。12yue8riyi“gansundaicha”shouruyuan,11rihuanzheniaosehuang,chuxianfanzao、yishimohu、binglizhengyangxingdengganxingnaobingbiaoxian,yiyuancaiqujijizhiliao,jiezhibaogaoshi(12yue15ri)huanzhezhengzhuangshangweihaozhuan。
三、建议
(一)医务人员在使用仙灵骨葆口服制剂前应详细了解患者疾病史及用药史,避免同时使用其他可导致肝损伤的药品,对有肝病史或肝生化指标异常的患者,应避免使用仙灵骨葆口服制剂。
(二)患者用药期间应定期监测肝生化指标;若出现肝生化指标异常或全身乏力、食欲不振、厌油、恶心、上腹胀痛、尿黄、目黄、皮肤黄染等可能与肝损伤有关的临床表现时,应立即停药并到医院就诊。
(san)yaopinshengchanqiyeyingdangjiaqiangyaopinbuliangfanyingjiance,jishixiudingxianlinggubaokoufuzhijideyaopinshuomingshu,gengxinxiangguandeyongyaofengxianxinxi,rubuliangfanying、jinji、zhuyishixiangdeng,yiyouxiaodefangshijiangxianlinggubaokoufuzhijideyongyaofengxiangaozhiyiwurenyuanhehuanzhe,jiadaheliyongyaoxuanchuan,zuidachengdubaozhanghuanzhedeyongyaoanquan。
guangxiliuyaojituangufenyouxiangongsi
dizhi:guangxiliuzhoushiguantangdadao68hao
邮编:545001
dianhua:+86-772-2514508
chuanzhen:+86-772-2514558
fanwubi:+86-772-2561873
tousurexian:+86-772-2520703